A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
7 Hills Pharma, LLC
Filamon LTD
Mayo Clinic
Washington University School of Medicine
University of Florida
Jonsson Comprehensive Cancer Center
University of Nebraska
Elephas
Novartis
Elephas
Cancer Research UK
Centre Hospitalier Universitaire de Nīmes
Massive Bio, Inc.
British Columbia Cancer Agency
Washington University School of Medicine
University of Florida
Delfi Diagnostics Inc.
Medicenna Therapeutics, Inc.
DEKA Biosciences
Columbia University
University of Arizona
Tempus AI
Revolution Medicines, Inc.
Arbeitsgemeinschaft medikamentoese Tumortherapie
Stanford University
Cedars-Sinai Medical Center
Mirai Medical
Taproot Health
VitaMed Research LLC
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
European Organisation for Research and Treatment of Cancer - EORTC
Sanguine Biosciences
National Cancer Institute (NCI)
Klus Pharma Inc.
Revolution Medicines, Inc.
Bristol-Myers Squibb
Revolution Medicines, Inc.
SpeciCare
Ohio State University Comprehensive Cancer Center
Lumos Pharma
M.D. Anderson Cancer Center
Stanford University
CureOne
sigma-tau i.f.r. S.p.A.
University of Texas Southwestern Medical Center
Santa Maria Biotherapeutics
OHSU Knight Cancer Institute
BIND Therapeutics
Stanford University
Case Comprehensive Cancer Center